Related Experiment Video
Updated: Jun 27, 2026
04:32
A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry
Published on: June 5, 2019
Immune thrombocytopenic purpura
1Departments of Medicine and Pathology, Faculty of Health Sciences, McMaster University Medical Centre and The Canadian Red Cross Blood Transfusion Service, Hamilton Centre.
Summary
Immune thrombocytopenia, a common cause of low platelet counts in rheumatic diseases, involves increased platelet destruction. Treatment includes corticosteroids, intravenous immunoglobulin, and splenectomy for refractory cases.
Area of Science:
- Rheumatology
- Hematology
- Immunology
Background:
- Thrombocytopenia frequently occurs in patients with rheumatic disorders.
- Common causes of thrombocytopenia include reduced platelet production, sequestration, or increased destruction.
- Immune thrombocytopenia is the most prevalent cause in outpatients, characterized by immune-mediated platelet destruction exceeding production.
Purpose of the Study:
- To discuss the diagnosis of immune thrombocytopenia.
- To elucidate the mechanisms underlying immune thrombocytopenia.
- To review potential therapies and their toxicities in patients with rheumatic disorders.
Main Methods:
- Literature review on immune thrombocytopenia diagnosis and mechanisms.
- Analysis of therapeutic strategies for immune thrombocytopenia.
- Evaluation of treatment toxicities in the context of rheumatic diseases.
Main Results:
- Immune thrombocytopenia is a significant complication in rheumatic diseases.
- Standard acute therapy involves corticosteroids and intravenous immunoglobulin.
- Splenectomy and other second-line therapies are options for refractory cases.
Conclusions:
- Understanding the mechanisms of immune thrombocytopenia is crucial for effective management.
- Therapeutic options range from acute treatments to second-line strategies for refractory disease.
- Careful consideration of potential treatment toxicities is essential, particularly in patients with rheumatic disorders.
Related Concept Videos
01:24Disorders of Hemostasis
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:22Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:18Structure and Function of Platelets
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
01:25Endocarditis II: Clinical Features of Infective Endocarditis
Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...